Detailansicht

Wissensnetz

Person

Michael Platten (1971-)

Name	Michael Platten
Zeit	1971- (Lebensdaten)
Ort	Bonn (Geburtsort) Heidelberg (Wirkungsort) Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof. Dr. med.
Variante	M. Platten
Beziehung	Jana K. Sonner (berufliche Beziehung) Klinikum Heidelberg (bis 31.08.2016) Medizin (Studienfach)
Weitere Angaben	Habil. Fachgebiet Allgemeine Neurologie an der Univ. Freiburg; Wissenschaftlicher Mitarbeiter ehemals leitender Oberarzt der Abteilung Neuroonkologie der Neurologischen Klinik der Universität Heidelberg; seit September 2016 Direktor der Neurologischen Klinik der Medizinischen Fakultät Mannheim der Universität Heidelberg
Datensatztyp	Person
GND-Nummer	121627780
Datensatz-ID	121627780
Beteiligt an alle anzeigen Immune cell dynamics in irradiated gliomas Sarcoma classification by DNA methylation profiling Bottom-up synthetic immunology Cranioencephalic functional lymphoid units in glioblastoma Tumor biomechanics as a novel imaging biomarker to assess response to immunotherapy in a murine glioma model Cell type mapping of inflammatory muscle diseases highlights selective myofiber vulnerability in inclusion body myositis Akuter ischämischer Schlaganfall und erhöhter Troponinwert – Update des Mannheimer Algorithmus L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy Development of MHC-dependent immunotherapy for gliomas Machine learning-guided prediction of tumor-reactive T cell receptors Concurrent gliomas in patients with multiple sclerosis Dietary L-Tryptophan consumption determines the number of colonic regulatory T cells and susceptibility to colitis via GPR15 INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas A H3K27M-targeted vaccine in adults with diffuse midline glioma Myeloid cell iron uptake pathways and paramagnetic rim formation in multiple sclerosis Approaches to address the immunogenicity and immunosuppressive features of Isocitrate Dehydrogenase 1 mutated gliomas Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline Dysfunctional dendritic cells limit antigen-specific T cell response in glioma Identification and characterization of T cell receptors reactive to the E7(11-19) epitope of HPV-16 Identification and validation of neoepitope-specific T cell receptors for glioma immunotherapy Identifizierung und Charakterisierung antigenspezifischer T-Zell-Antworten gegen Glioblastome Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions Neuroonkologie : Patientenzentrierte Pfade für Diagnostik und Therapie Neuroonkologie : Patientenzentrierte Pfade für Diagnostik und Therapie Non-invasive tracking of T cell recruitment to the tumor microenvironment in a murine glioma model by high field cellular magnetic resonance imaging T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients Therapie und Verlauf neurologischer Erkrankungen Therapie und Verlauf neurologischer Erkrankungen Therapie und Verlauf neurologischer Erkrankungen Veränderungen des Tumormikromilieus durch zelluläre Immuntherapien in experimentellen Tumormodellen Clinical and Translational Advances in Glioma Immunotherapy Activation of non-classical NMDA receptors by glycine impairs barrier function of brain endothelial cells Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas The remains of the day: neuropsychological findings in postacute transient global amnesia MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions Benefit bei IDH-mutierten Astrozytomen Common T-Cell-Receptor motifs and features in patients with cytomegalovirus (CMV)-seronegative end-stage renal disease receiving a peptide vaccination against CMV Evaluating the role of the aryl hydrocarbon receptor and CXCL10 in regulating the tumour immune microenvironment Identification of myeloid cell targets for cancer immunotherapy using CRISPR screening In vivo Darstellung von Immunzellen mittels Eisenoxid-Nanopartikeln und MRT in einem Modell der Multiplen Sklerose The effect of dietary tryptophan deprivation on autoreactive T cells and the gut microbiome Association of iron rim lesions with brain and cervical cord volume in relapsing multiple sclerosis Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper) Intrathecal activation of CD8 + memory T cells in IgG4‐related disease of the brain parenchyma Chronobiology of transient global amnesia Akuter ischämischer Schlaganfall und Troponinerhöhung: Diagnostische Abklärung und therapeutische Konsequenzen A vaccine targeting mutant IDH1 in newly diagnosed glioma Charakterisierung der TDO-vermittelten Immunsuppression in experimentellen Gliomen Comparative evaluation of T cell receptors in experimental glioma-draining lymph nodes Identification of Myeloid Cell Targets for Cancer Immunotherapy Major Histocompatibility Complex Class II Antigen Responses as Drivers of Brain Tumor Immunity Modulation of antitumor immunity by isocitrate dehydrogenase-mutated tumors Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Michael Platten (1971-)

Immune cell dynamics in irradiated gliomas

Sarcoma classification by DNA methylation profiling

Bottom-up synthetic immunology

Cranioencephalic functional lymphoid units in glioblastoma

Tumor biomechanics as a novel imaging biomarker to assess response to immunotherapy in a murine glioma model

Cell type mapping of inflammatory muscle diseases highlights selective myofiber vulnerability in inclusion body myositis

Akuter ischämischer Schlaganfall und erhöhter Troponinwert – Update des Mannheimer Algorithmus

L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial

Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy

Development of MHC-dependent immunotherapy for gliomas

Machine learning-guided prediction of tumor-reactive T cell receptors

Concurrent gliomas in patients with multiple sclerosis

Dietary L-Tryptophan consumption determines the number of colonic regulatory T cells and susceptibility to colitis via GPR15

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas

A H3K27M-targeted vaccine in adults with diffuse midline glioma

Myeloid cell iron uptake pathways and paramagnetic rim formation in multiple sclerosis

Approaches to address the immunogenicity and immunosuppressive features of Isocitrate Dehydrogenase 1 mutated gliomas

Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline

Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline

Dysfunctional dendritic cells limit antigen-specific T cell response in glioma

Identification and characterization of T cell receptors reactive to the E7(11-19) epitope of HPV-16

Identification and validation of neoepitope-specific T cell receptors for glioma immunotherapy

Identifizierung und Charakterisierung antigenspezifischer T-Zell-Antworten gegen Glioblastome

Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions

Neuroonkologie : Patientenzentrierte Pfade für Diagnostik und Therapie

Neuroonkologie : Patientenzentrierte Pfade für Diagnostik und Therapie

Non-invasive tracking of T cell recruitment to the tumor microenvironment in a murine glioma model by high field cellular magnetic resonance imaging

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

Therapie und Verlauf neurologischer Erkrankungen

Therapie und Verlauf neurologischer Erkrankungen

Therapie und Verlauf neurologischer Erkrankungen

Veränderungen des Tumormikromilieus durch zelluläre Immuntherapien in experimentellen Tumormodellen

Clinical and Translational Advances in Glioma Immunotherapy

Activation of non-classical NMDA receptors by glycine impairs barrier function of brain endothelial cells

Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

The remains of the day: neuropsychological findings in postacute transient global amnesia

MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions

Benefit bei IDH-mutierten Astrozytomen

Common T-Cell-Receptor motifs and features in patients with cytomegalovirus (CMV)-seronegative end-stage renal disease receiving a peptide vaccination against CMV

Evaluating the role of the aryl hydrocarbon receptor and CXCL10 in regulating the tumour immune microenvironment

Identification of myeloid cell targets for cancer immunotherapy using CRISPR screening

In vivo Darstellung von Immunzellen mittels Eisenoxid-Nanopartikeln und MRT in einem Modell der Multiplen Sklerose

The effect of dietary tryptophan deprivation on autoreactive T cells and the gut microbiome

Association of iron rim lesions with brain and cervical cord volume in relapsing multiple sclerosis

Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)

Intrathecal activation of CD8 + memory T cells in IgG4‐related disease of the brain parenchyma

Chronobiology of transient global amnesia

Akuter ischämischer Schlaganfall und Troponinerhöhung: Diagnostische Abklärung und therapeutische Konsequenzen

A vaccine targeting mutant IDH1 in newly diagnosed glioma

Charakterisierung der TDO-vermittelten Immunsuppression in experimentellen Gliomen

Comparative evaluation of T cell receptors in experimental glioma-draining lymph nodes

Identification of Myeloid Cell Targets for Cancer Immunotherapy

Major Histocompatibility Complex Class II Antigen Responses as Drivers of Brain Tumor Immunity

Modulation of antitumor immunity by isocitrate dehydrogenase-mutated tumors

Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma